Michael Goldberg - Echo Therapeutics Director
Director
Dr. Michael M. Goldberg M.D. is Independent Director of the Echo Therapeutics Inc.. Dr. Goldberg was appointed by our Board of Directors in February 2014 to fill a vacancy and was elected a director by our stockholders on June 19 2014. He was elected the Chairman of the Board on January 5 2015. He was a Managing Member of Montaur Capital LLC since January 2014 and was a Managing Partner of Montaur Capital Partners from February 2007 to December 2013. Prior to that Dr. Goldberg was with Emisphere Technologies Inc. serving as Chief Executive Officer from August 1990 to January 2007 Chairman of the Board of Directors from November 1991 to January 2007 and President from August 1990 to October 1995. Before joining Emisphere Dr. Goldberg served as Vice President of The First Boston Corporationration where he was a founding member of the Healthcare Banking Group. Dr. Goldberg currently serves on the board of Navidea Biopharmaceuticals. He was a Director of Alliqua Inc. Urigen Pharmaceuticals Inc. Adventrx Pharmaceuticals Inc. and several private companies since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 732-201-4189 |
| Web | http://www.echotx.com |
Michael Goldberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Goldberg against Echo Therapeutics stock is an integral part of due diligence when investing in Echo Therapeutics. Michael Goldberg insider activity provides valuable insight into whether Echo Therapeutics is net buyers or sellers over its current business cycle. Note, Echo Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Echo Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Goldberg over two weeks ago Acquisition by Michael Goldberg of 3686 shares of Caredx subject to Rule 16b-3 |
Echo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (359.77) % which means that it has lost $359.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.649) %, meaning that it created substantial loss on money invested by shareholders. Echo Therapeutics' management efficiency ratios could be used to measure how well Echo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.52 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Echo Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Echo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Echo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Echo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Echo to invest in growth at high rates of return. When we think about Echo Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 14 records | DIRECTOR Age | ||
| James Kern | Tscan Therapeutics | 49 | |
| Admiral Giambastiani | Tscan Therapeutics | N/A | |
| Dorothy Clarke | Eterna Therapeutics | 58 | |
| Nancy Hawthorne | Tscan Therapeutics | 66 | |
| David Tierney | Catalyst Pharmaceuticals | 54 | |
| Deborah McAneny | Tscan Therapeutics | 58 | |
| Keith Hughes | Tscan Therapeutics | 70 | |
| Donald Denkhaus | Catalyst Pharmaceuticals | 72 | |
| David Downes | Tscan Therapeutics | 76 | |
| Philip Coelho | Catalyst Pharmaceuticals | 74 | |
| David Southwell | Tscan Therapeutics | 63 | |
| Charles OKeeffe | Catalyst Pharmaceuticals | 78 | |
| Richard Daly | Catalyst Pharmaceuticals | 57 | |
| Jane Nelson | Tscan Therapeutics | N/A | |
Management Performance
| Return On Equity | -3.65 | |||
| Return On Asset | -359.77 |
Echo Therapeutics Leadership Team
Elected by the shareholders, the Echo Therapeutics' board of directors comprises two types of representatives: Echo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Echo. The board's role is to monitor Echo Therapeutics' management team and ensure that shareholders' interests are well served. Echo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Echo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Goldberg, Director | ||
| Scott Hollander, CEO and President and Director | ||
| Elazer Edelman, Director | ||
| Christine Olimpio, Director of Investor Relations and Corporate Communications | ||
| Alan Schoenbart, CFO | ||
| Shepard Goldberg, Director |
Echo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Echo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.65 | |||
| Return On Asset | -359.77 | |||
| Current Valuation | 3.43 M | |||
| Shares Outstanding | 12 M | |||
| Number Of Shares Shorted | 273.27 K | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 3.11 X | |||
| Price To Sales | 990.09 X | |||
| Revenue | 5.12 K | |||
| Gross Profit | 5.12 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Echo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Echo Therapeutics' short interest history, or implied volatility extrapolated from Echo Therapeutics options trading.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Echo Stock
If you are still planning to invest in Echo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Echo Therapeutics' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |